Photo: Getty Images
CAMBRIDGE, Mass. (WBZ NewsRadio) — Cambridge-based Moderna announced Thursday its COVID-19 vaccine is 93% effective six months after the second dose is administered.
"I am proud of the progress our teams at Moderna have made in the past quarter in advancing our development pipeline while addressing a global pandemic and quickly establishing global manufacturing and commercial organizations," Moderna CEO Stéphane Bancel said in a statement. "We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant."
Read More: Fall Out Boy Not Performing At Fenway Because Of Covid
Moderna also announced a study showed that three candidates for a booster shot had robust responses to COVID-19 variants, including the Delta variant.
In a presentation on earnings, the company said it believes that the Delta variant will lead to an increase in breakthrough cases, and therefore a booster "will likely be necessary prior to the winter season."
Moderna's vaccine is currently under emergency use authorization. The company began the submission process for full approval on June 1, and expects to complete its submission this month.
Follow WBZ NewsRadio: Facebook | Twitter | Instagram | iHeartmedia App